Abstract
Forkhead O transcription factors (FOXO) are critical for the regulation of cell cycle arrest, cell death, and DNA damage repair. Inactivation of FOXO proteins may be associated with tumorigenesis, including breast cancer, prostate cancer, glioblastoma, rhabdomyosarcoma, and leukemia. Accumulated evidence shows that activation of oncogenic pathways such as phosphoinositide-3-kinase/AKT/IKK or RAS/mitogen-activated protein kinase suppresses FOXO transcriptional activity through the phosphorylation of FOXOs at different sites that ultimately leads to nuclear exclusion and degradation of FOXOs. In addition, posttranslational modifications of FOXOs such as acetylation, methylation and ubiquitination also contribute to modulating FOXO3a functions. Several anti-cancer drugs like paclitaxel, imatinib, and doxorubicin activate FOXO3a by counteracting those oncogenic pathways which restrain FOXOs functions. In this review, we will illustrate the regulation of FOXOs and reveal potential therapeutics that target FOXOs for cancer treatment.
Keywords: Forkhead transcriptional factor, breast cancer, cancer therapy, glioblastoma, rhabdomyosarcoma, leukemia, FoxO3, AZD6244, NSCLC
Current Drug Targets
Title: Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Volume: 12 Issue: 9
Author(s): Jer-Yen Yang and Mien-Chie Hung
Affiliation:
Keywords: Forkhead transcriptional factor, breast cancer, cancer therapy, glioblastoma, rhabdomyosarcoma, leukemia, FoxO3, AZD6244, NSCLC
Abstract: Forkhead O transcription factors (FOXO) are critical for the regulation of cell cycle arrest, cell death, and DNA damage repair. Inactivation of FOXO proteins may be associated with tumorigenesis, including breast cancer, prostate cancer, glioblastoma, rhabdomyosarcoma, and leukemia. Accumulated evidence shows that activation of oncogenic pathways such as phosphoinositide-3-kinase/AKT/IKK or RAS/mitogen-activated protein kinase suppresses FOXO transcriptional activity through the phosphorylation of FOXOs at different sites that ultimately leads to nuclear exclusion and degradation of FOXOs. In addition, posttranslational modifications of FOXOs such as acetylation, methylation and ubiquitination also contribute to modulating FOXO3a functions. Several anti-cancer drugs like paclitaxel, imatinib, and doxorubicin activate FOXO3a by counteracting those oncogenic pathways which restrain FOXOs functions. In this review, we will illustrate the regulation of FOXOs and reveal potential therapeutics that target FOXOs for cancer treatment.
Export Options
About this article
Cite this article as:
Yang Jer-Yen and Hung Mien-Chie, Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy, Current Drug Targets 2011; 12 (9) . https://dx.doi.org/10.2174/138945011796150299
DOI https://dx.doi.org/10.2174/138945011796150299 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia
Current Nanoscience Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Microarray: An Approach for Current Drug Targets
Current Drug Metabolism Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy
Current Pharmaceutical Design Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets Exosome-like Nanovesicles Isolated from Citrus limon L. Exert Antioxidative Effect
Current Pharmaceutical Biotechnology Perinatal Management of Fetal Tumors
Current Pediatric Reviews Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Current Pharmaceutical Design Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin
Current Vascular Pharmacology The Tumor Suppressor, p53 Regulates the γA-Crystallin Gene During Mouse Lens Development
Current Molecular Medicine Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry MicroRNAs as Cancer Biomarkers
MicroRNA Targeting Angiogenesis in Soft Tissue Sarcomas
Current Angiogenesis (Discontinued)